stockportfolio.pro
Design Therapeutics, Inc. (DSGN)
Healthcare · Biotechnology · NasdaqGS
Design Therapeutics, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $226,000 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-8.28M | $-35.53M | $-63.31M | $-66.86M | $-49.59M | $-69.79M |
| Net margin | -3663.7% | — | — | — | — | — |
Source: Design Therapeutics, Inc. SEC filings (10-K).
Explore 6 years of Design Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DSGN in your portfolio →
Design Therapeutics, Inc. financial history by metric
About Design Therapeutics, Inc.
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
Design Therapeutics, Inc. — frequently asked questions
What is Design Therapeutics, Inc.'s revenue?
Design Therapeutics, Inc. (DSGN) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Design Therapeutics, Inc. profitable?
No — DSGN reported a net loss of $-69.79M in fiscal 2025.
What is DSGN's P/E ratio?
Design Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Design Therapeutics, Inc. have?
As of fiscal year 2025, DSGN carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Design Therapeutics, Inc.'s market cap?
Design Therapeutics, Inc. (DSGN) has a market capitalization of about $647.68M, based on the latest data in our nightly-refreshed cache.
When does Design Therapeutics, Inc.'s fiscal year end?
DSGN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Design Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.